retatrutide ada 2025 results Phase 3: 60% Achieved Surgical-Level Weight Loss ADA 2026 Obesity Drug Updates:

Bariatric surgery is the most effective intervention for weight loss in obese patients, and it leads to improvement in multiple obesity-related conditions, including remission of diabetes.

The effects were seen alongside weight loss and independently of it.

Get insights on navigating GLP-1 antagonist shortages and compounds as we navigate demand and supply challenges.

While the world has focused on the battle between injectables and oral tablets, the "Mucosal Frontier" addresses the three biggest hurdles in peptide therapy: 1 Bioavailability: By utilizing a mucosal delivery platform, the drug avoids first-pass metabolism in the liver, potentially offering a more efficient way for the body to utilize the peptide compared to traditional oral versions

The GLP-1 Diet Food Market worth USD 3.1 billion in 2026 is growing at a CAGR of 17.4% to reach USD 15.4 billion by 2036

Hims & Hers Health runs a telehealth and consumer wellness platform that connects patients with...